137.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché A Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$135.05
Aprire:
$134.22
Volume 24 ore:
2.92M
Relative Volume:
1.29
Capitalizzazione di mercato:
$38.81B
Reddito:
$7.23B
Utile/perdita netta:
$1.41B
Rapporto P/E:
27.60
EPS:
4.979
Flusso di cassa netto:
$1.09B
1 W Prestazione:
+18.61%
1M Prestazione:
+19.98%
6M Prestazione:
-7.95%
1 anno Prestazione:
+21.85%
Agilent Technologies Inc Stock (A) Company Profile
Nome
Agilent Technologies Inc
Settore
Industria
Telefono
(408) 345-8886
Indirizzo
5301 STEVENS CREEK BLVD, SANTA CLARA, CA
Compare A vs TMO, DHR, IDXX, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
A
Agilent Technologies Inc
|
137.40 | 38.14B | 7.23B | 1.41B | 1.09B | 4.979 |
|
TMO
Thermo Fisher Scientific Inc
|
473.95 | 179.15B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
178.08 | 124.65B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
560.73 | 43.45B | 4.45B | 1.10B | 1.06B | 13.59 |
|
WAT
Waters Corp
|
379.77 | 36.52B | 3.77B | 449.25M | 240.68M | 7.8556 |
Agilent Technologies Inc Stock (A) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-20 | Iniziato | HSBC Securities | Buy |
| 2026-01-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-12-15 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-02 | Iniziato | Morgan Stanley | Overweight |
| 2025-10-08 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-08 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-10 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-04-05 | Aggiornamento | Stifel | Hold → Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-17 | Downgrade | UBS | Buy → Neutral |
| 2023-09-28 | Iniziato | Bernstein | Mkt Perform |
| 2023-07-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-05-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | Citigroup | Neutral |
| 2023-05-24 | Reiterato | Credit Suisse | Outperform |
| 2023-05-24 | Reiterato | Evercore ISI | Outperform |
| 2023-05-24 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-24 | Reiterato | Robert W. Baird | Outperform |
| 2023-05-24 | Reiterato | SVB Securities | Outperform |
| 2023-05-24 | Reiterato | Stifel | Hold |
| 2023-05-24 | Reiterato | TD Cowen | Outperform |
| 2023-05-24 | Reiterato | Wells Fargo | Overweight |
| 2023-05-11 | Iniziato | Barclays | Equal Weight |
| 2023-01-10 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-07-20 | Iniziato | UBS | Buy |
| 2022-07-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-02-23 | Reiterato | BofA Securities | Buy |
| 2022-02-23 | Reiterato | Citigroup | Buy |
| 2022-02-23 | Reiterato | Cowen | Outperform |
| 2022-02-23 | Reiterato | Evercore ISI | Outperform |
| 2022-02-23 | Reiterato | Stifel | Hold |
| 2022-02-23 | Reiterato | Wells Fargo | Overweight |
| 2021-11-23 | Reiterato | BofA Securities | Buy |
| 2021-11-23 | Reiterato | Cowen | Outperform |
| 2021-11-23 | Reiterato | Stifel | Hold |
| 2021-03-18 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-25 | Aggiornamento | UBS | Neutral → Buy |
| 2020-11-17 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-09-30 | Iniziato | Atlantic Equities | Neutral |
| 2020-08-19 | Reiterato | BofA Securities | Neutral |
| 2020-08-19 | Reiterato | Citigroup | Neutral |
| 2020-08-19 | Reiterato | Jefferies | Buy |
| 2020-08-19 | Reiterato | Robert W. Baird | Outperform |
| 2020-08-19 | Reiterato | SVB Leerink | Outperform |
| 2020-08-19 | Reiterato | Stifel | Hold |
| 2020-08-19 | Reiterato | Wells Fargo | Overweight |
| 2020-02-24 | Downgrade | Needham | Buy → Hold |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-11-26 | Reiterato | Needham | Buy |
| 2019-11-15 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | UBS | Buy → Neutral |
| 2019-07-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-15 | Downgrade | Barclays | Overweight → Equal Weight |
Mostra tutto
Agilent Technologies Inc Borsa (A) Ultime notizie
Why Agilent Technologies stock triumphed on Thursday - MSN
Agilent partners with OpenAI and BCG to embed AI across scientific instruments and operations - The Business Journals
Agilent Technologies Inc. stock (US00846U1016): Insider share sale follows FDA approval and guidance - AD HOC NEWS
Agilent stock is having its best day since 2002. Earnings leave Wall Street with ‘little to pick at.’ - MSN
HSBC Adjusts Price Target on Agilent Technologies to $165 From $180, Maintains Buy Rating - Moomoo
Agilent Technologies (A) Slid Over Investors’ Skepticism over Acquisition - Insider Monkey
Agilent Technologies (A) Declined in Q1 Amid QIAGEN Acquisition Speculation - Yahoo Finance
Agilent partners with OpenAI and BCG to deploy AI solutions By Investing.com - Investing.com Canada
Agilent partners with OpenAI and BCG to deploy AI solutions - Investing.com
Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation - The Joplin Globe
OpenAI joins Agilent lab tools in new push to speed up scientific discovery - Stock Titan
Agilent upgraded at BofA on FQ2 beats, growth - MSN
FDA approves Agilent’s PD-L1 test expansion for four cancers By Investing.com - Investing.com Nigeria
FDA approves Agilent’s PD-L1 test expansion for four cancers - Investing.com
FDA broadens cancer test to find more patients eligible for Keytruda - Stock Titan
Agilent (NYSE: A) director trims stake with 1,600-share stock sale - Stock Titan
Agilent introduces the 9500 Triple Quadrupole ICP-MS – Redefining trace element analysis - SelectScience
BofA Securities Adjusts Agilent Technologies PT to $155 From $145 - marketscreener.com
Is Now The Time To Look At Buying Agilent Technologies, Inc. (NYSE:A)? - Yahoo Finance
Agilent Technologies Q2 2026 Financial Report – Earnings, Revenue, and SEC Filing Highlights - Minichart
Agilent Q2 earnings call shows Ignite driving a higher outlook - MSN
Agilent Technologies Inc. stock (US00846U1016): shares advance after stronger Q2 2026 results and hi - AD HOC NEWS
Agilent presents its integrated mass spectrometry and chromatography solutions at ASMS 2026 - SelectScience
Agilent Technologies : and Sound Analytics Collaborate to Advance LC/MS Workflows for Drug Metabolism Research - marketscreener.com
Agilent Technologies 2Q 2026: Revenue $1.84B, EPS $1.2— 10-Q Summary - TradingView
Agilent (NYSE: A) posts profit growth, $950M Biocare deal and strong cash - Stock Titan
Jim Cramer on Agilent: “There Might Be an Opportunity” - Insider Monkey
Agilent Technologies Inc. stock (US00846U1016): shares in focus after recent earnings and analyst up - AD HOC NEWS
Agilent (A) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Agilent Technologies (A) Is Up 17.9% After Raising 2026 Outlook And Expanding Lab Informatics Portfolio - simplywall.st
Agilent launches new GC Systems to improve laboratory efficiency and data quality - BioSpectrum India
Agilent Q2 Earnings Call Shows Ignite Driving a Higher Outlook - Eastern Progress
Agilent Technologies, Inc. (A) Stock Analysis: Strong Buy Ratings and 19% Potential Upside Drive Investor Interest - DirectorsTalk Interviews
Agilent Technologies Opens with 16.54% Gain, Outperforming S&P 500's 0.58% Rise - Markets Mojo
Agilent Technologies Q2 earnings beat estimates, revenues up Y/Y - MSN
Agilent Technologies Inc. stock (US00846U1016): Technical picture in focus after recent trading cons - AD HOC NEWS
Is It Too Late To Consider Agilent Technologies (A) After Its Recent Share Price Surge - simplywall.st
Mettler-Toledo International vs Agilent Technologies: Which Is the Stronger Buy Today? - Trefis
7-Day Rally Sends Agilent Technologies Stock Up 23% - Trefis
Agilent Technologies Stock 7-Day Winning Spree: Stock Climbs 23% - Trefis
Stocks making big moves this week: Viasat, Agilent, Verra Mobility, Torrid, and Zscaler - Yahoo Finance
A (NYSE: A) files Form 144 notice listing 1,600 shares and vesting entries - Stock Titan
A Quick Look at Today's Ratings for Agilent Technologies(A.US), With a Forecast Between $145 to $170 - Moomoo
BofA Adjusts Price Target on Agilent Technologies to $145 From $150 - marketscreener.com
Agilent Technologies (A) Margin Gains Reinforce Bullish Recurring Revenue Narrative After Q2 2026 Results - simplywall.st
Agilent Technologies : Showcases Integrated Mass Spectrometry and Chromatography Solutions at ASMS 2026 - marketscreener.com
Agilent Technologies Stock (+17%): Q2 Earnings Beat and Raised FY26 Guidance - Trefis
Stock Market Today: S&P 500, Dow Futures Inch Up As US-Iran Deal Awaits Trump Approval — Dell, Agilent, Hewlett Packard Enterprise In Focus - Benzinga
Top Agilent Technologies (A) Competitors 2026 - MarketBeat
Agilent Technologies Stock Surges 22%, With A 6-Day Winning Spree - Trefis
Agilent Technologies Stock Rockets 22% With 6-Day Winning Streak - Trefis
Agilent Technologies Inc Azioni (A) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):